Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Zaaijer, M. Koppelman, C. Farrington (2004)
Parvovirus B19 viraemia in Dutch blood donorsEpidemiology and Infection, 132
W. Ballou, J. Reed, W. Noble, N. Young, S. Koenig (2003)
Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.The Journal of infectious diseases, 187 4
D. Arnold, P. Neame, Ralph Meyer, P. Soamboonsrup, K. Luinstra, P. O’Hoski, J. Garner, R. Foley (2005)
Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infectionTransfusion, 45
J. Blümel, A. Eis-Hübinger, A. Stühler, Claudia Bönsch, M. Gessner, J. Löwer (2005)
Characterization of Parvovirus B19 Genotype 2 in KU812Ep6 CellsJournal of Virology, 79
W. Hitzler, Stefan Runkel (2002)
Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reactionVox Sanguinis, 82
Hiroyuki Sato, F. Takakura, E. Kojima, K. Fukada, K. Okochi, Y. Maeda (1995)
Screening of blood donors for human parvovirus B19The Lancet, 346
Y. Munakata, Takako Saito-Ito, Keiko Kumura-Ishii, Jie Huang, T. Kodera, T. Ishii, Y. Hirabayashi, Y. Koyanagi, Takeshi Sasaki (2005)
Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection.Blood, 106 10
(2000)
Phase IV study of Plas1 SD: hepatitis A (HAV) and parvovirus B19
N. Yaegashi, H. Shiraishi, T. Takeshita, M. Nakamura, A. Yajima, K. Sugamura (1989)
Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liverJournal of Virology, 63
F. Corbin (2002)
Pathogen inactivation of blood components: Current status and introduction of an approach using riboflavin as a photosensitizerInternational Journal of Hematology, 76
D. Lyon, C. Chapman, Carol Martin, K. Brown, J. Clewley, A. Flower, V. Mitchell (1989)
SYMPTOMATIC PARVOVIRUS B19 INFECTION AND HEAT-TREATED FACTOR IX CONCENTRATEThe Lancet, 333
Armen Parsyan, S. Kerr, S. Owusu-Ofori, G. Elliott, J. Allain (2006)
Reactivity of Genotype-Specific Recombinant Proteins of Human Erythrovirus B19 with Plasmas from Areas Where Genotype 1 or 3 Is EndemicJournal of Clinical Microbiology, 44
Chuan-ging Wu, B. Mason, J. Jong, D. Erdman, Laurel Mckernan, Meredith Oakley, M. Soucie, B. Evatt, M. Yu (2005)
Parvovirus B19 transmission by a high‐purity factor VIII concentrateTransfusion, 45
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini (1994)
Eliminating parvovirus B19 from blood productsThe Lancet, 343
N. Yageashi, Takenari Niinuma, H. Chisaka, Tatsuya Watanabe, S. Uehara, K. Okamura, S. Moffatt, K. Sugamura, A. Yajima (1998)
The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis.The Journal of infection, 37 1
J. Lefrère, A. Servant‐Delmas, D. Candotti, M. Mariotti, I. Thomas, Y. Brossard, F. Lefrère, R. Girot, J. Allain, S. Laperche (2005)
Persistent B19 infection in immunocompetent individuals: implications for transfusion safety.Blood, 106 8
J. Jordan (2000)
Comparison of a Baculovirus-Based VP2 Enzyme Immunoassay (EIA) to an Escherichia coli-Based VP1 EIA for Detection of Human Parvovirus B19 Immunoglobulin M and Immunoglobulin G in Sera of Pregnant WomenJournal of Clinical Microbiology, 38
G. Gallinella, E. Manaresi, S. Venturoli, G. Grazi, M. Musiani, M. Zerbini (1999)
Occurrence and Clinical Role of Active Parvovirus B19 Infection in Transplant RecipientsEuropean Journal of Clinical Microbiology and Infectious Diseases, 18
B. Kaufmann, A. Simpson, M. Rossmann (2004)
The structure of human parvovirus B19.Proceedings of the National Academy of Sciences of the United States of America, 101 32
A. Azzi, A. Azzi, Massirno Morfini, Massirno Morfini, P. Mannucci, P. Mannucci (1999)
The transfusion-associated transmission of parvovirus B19.Transfusion medicine reviews, 13 3
D. Candotti, N. Etiz, Armen Parsyan, J. Allain (2004)
Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor SamplesJournal of Virology, 78
G. Kurtzman, N. Frickhofen, J. Kimball, D. Jenkins, A. Nienhuis, N. Young (1989)
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.The New England journal of medicine, 321 8
P. Daly, A. Corcoran, Bernard Mahon, Sean Doyle (2002)
High-Sensitivity PCR Detection of Parvovirus B19 in PlasmaJournal of Clinical Microbiology, 40
A. Behzad-Behbahani, R. Pouransari, S. Tabei, M. Rahiminejad, M. Robati, R. Yaghobi, H. Nourani, M. Ramzi, A. Farhadi-Andarabi, A. Mojiri, M. Rahsaz, M. Banihashemi, N. Zare (2005)
Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation.Transplantation proceedings, 37 7
P. Norja, K. Hokynar, L. Aaltonen, Renwei Chen, A. Ranki, E. Partio, O. Kiviluoto, I. Davidkin, T. Leivo, A. Eis-Hübinger, B. Schneider, H. Fischer, R. Tolba, O. Vapalahti, A. Vaheri, M. Söderlund-Venermo, K. Hedman (2006)
Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.Proceedings of the National Academy of Sciences of the United States of America, 103 19
H. Rollag, G. Patou, J. Pattison, M. Degré, Stein Evensen, S. Frøland, A. Glomstein (1991)
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.Scandinavian journal of infectious diseases, 23 6
K. Broliden (2001)
Parvovirus B19 infection in pediatric solid‐organ and bone marrow transplantationPediatric Transplantation, 5
BJ Cohen, S. Beard, WA Knowles, J. Ellis, D. Joske, J. Goldman, P. Hewitt, K. Ward (1997)
Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusionTransfusion, 37
Y. Cossart (2004)
Human Parvovirus B19American Journal of Transplantation, 4
S. Shimomura, N. Komatsu, N. Frickhofen, S. Anderson, S. Kajigaya, N. Young (1992)
First continuous propagation of B19 parvovirus in a cell line.Blood, 79 1
T. Kreil, A. Wieser, A. Berting, M. Spruth, Christian Medek, G. Pölsler, Theodor Gaida, T. Hämmerle, W. Teschner, H. Schwarz, P. Barrett (2006)
Removal of small nonenveloped viruses by antibody‐enhanced nanofiltration during the manufacture of plasma derivativesTransfusion, 46
F. Terpstra, J. Parkkinen, H. Tölö, A. Koenderman, H. Hart, L. Bonsdorff, E. Törmä, F. Engelenburg (2006)
Viral safety of Nanogam®, a new 15 nm‐filtered liquid immunoglobulin productVox Sanguinis, 90
A. Eis-Hübinger, J. Oldenburg, H. Brackmann, B. Matz, K. Schneweis (1996)
The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population.Zentralblatt fur Bakteriologie : international journal of medical microbiology, 284 2-3
Y. Cossart, B. Cant, A. Field, D. Widdows (1975)
PARVOVIRUS-LIKE PARTICLES IN HUMAN SERAThe Lancet, 305
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini, R. Musso, R. Santoro, M. Schiavoni (1997)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.Transfusion, 37 5
T. Yee, B. Cohen, K. Pasi, C. Lee (1996)
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 93
G. Bansal, Jacqueline Hatfield, F. Dunn, A. Kramer, F. Brady, C. Riggin, M. Collett, K. Yoshimoto, S. Kajigaya, N. Young (1993)
Candidate recombinant vaccine for human B19 parvovirus.The Journal of infectious diseases, 167 5
Lily Lin, C. Hanson, H. Alter, V. Jauvin, K. Bernard, K. Murthy, P. Metzel, L. Corash (2005)
Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet lightTransfusion, 45
C. Srivastava, Shangzhen Zhou, Nikhil Munshi, A. Srivastava (1992)
Parvovirus B19 replication in human umbilical cord blood cells.Virology, 189 2
Takahashi Takeshi, K. Ozawa, Keisuke Takahashi, S. Asano, F. Takaku (1990)
Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation.Blood, 75 3
L. Shackelton, E. Holmes (2006)
Phylogenetic Evidence for the Rapid Evolution of Human B19 ErythrovirusJournal of Virology, 80
K. Peerlinck, P. Goubau, R. Reybrouck, J. Desmyter, J. Vermylen (1995)
Parvovirus B19 Antibodies in Patients with Haemophilia AThrombosis and Haemostasis, 73
S. Kerr, G. O’Keeffe, C. Kilty, Sean Doyle (1999)
Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgGJournal of Medical Virology, 57
S. Sanabani, W. Neto, J. Pereira, E. Sabino (2006)
Sequence Variability of Human Erythroviruses Present in Bone Marrow of Brazilian Patients with Various Parvovirus B19-Related Hematological SymptomsJournal of Clinical Microbiology, 44
(2004)
Distribution of blood components recipients according to immune status
A. Isa, O. Norbeck, T. Hirbod, A. Lundqvist, Victoria Kasprowicz, P. Bowness, P. Klenerman, K. Broliden, T. Tolfvenstam (2006)
Aberrant cellular immune responses in humans infected persistently with parvovirus B19Journal of Medical Virology, 78
A. Butchko, J. Jordan (2004)
Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant WomenJournal of Clinical Microbiology, 42
L. Murer, G. Zacchello, D. Bianchi, R. Dall'amico, G. Montini, B. Andreetta, M. Perini, Elisabetta Dossi, G. Zanon, F. Zacchello (2000)
Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation.Journal of the American Society of Nephrology : JASN, 11 6
M. Bluth, K. Norowitz, S. Chice, V. Shah, M. Nowakowski, H. Durkin, T. Smith‐Norowitz (2005)
IgE, CD8+CD60+ T Cells and IFN-α in Human Immunity to Parvovirus B19 in Selective IgA DeficiencyHuman Immunology, 66
Aris Lazo, Jodie Tassello, V. Jayarama, A. Ohagen, V. Gibaja, E. Kramer, A. Marmorato, D. Billia-Shaveet, A. Purmal, F. Brown, J. Chapman (2002)
Broad‐spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistryVox Sanguinis, 83
K. Hokynar, M. Söderlund-Venermo, M. Pesonen, A. Ranki, O. Kiviluoto, E. Partio, K. Hedman (2002)
A new parvovirus genotype persistent in human skin.Virology, 302 2
E. Manaresi, G. Gallinella, S. Venturoli, M. Zerbini, M. Musiani (2004)
Detection of parvovirus B19 IgG: choice of antigens and serological tests.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 29 1
G. Mariani, T. Paolantonio, R. Baklaya, M. Morfini, P. Mannucci (1993)
Prospective study of the evaluation of hepatitis C virus infectivity in a high‐purity, solvent/detergent‐treated factor VIII concentrate: parallel evaluation of other markers for lipid‐enveloped and non‐lipid‐ enveloped viruses.Transfusion, 33
Larry Anderson, C. Tsou, Robert Parker, Terence Chorba, H. Wulff, P. Tattersall, P. Mortimer (1986)
Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assayJournal of Clinical Microbiology, 24
A. Yango, Paul Morrissey, R. Gohh, A. Wahbeh (2002)
Donor‐transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunctionTransplant Infectious Disease, 4
M. Tsujimura, K. Matsushita, H. Shiraki, H. Sato, K. Okochi, Y. Maeda (1995)
Human Parvovirus B19 Infection in Blood DonorsVox Sanguinis, 69
K. Hokynar, P. Norja, H. Laitinen, P. Palomäki, A. Garbarg‐Chenon, A. Ranki, K. Hedman, M. Söderlund-Venermo (2004)
Detection and Differentiation of Human Parvovirus Variants by Commercial Quantitative Real-Time PCR TestsJournal of Clinical Microbiology, 42
John Saldanha (2001)
Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 20 1-2
I. Schmidt, Johannes Blümel, H. Seitz, H. Willkommen, Johannes Löwer (2001)
Parvovirus B19 DNA in plasma pools and plasma derivativesVox Sanguinis, 81
I. Thomas, M. Giambattista, C. Gérard, E. Mathys, V. Hougardy, B. Latour, T. Branckaert, Ruth Laub (2003)
Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non‐structural viral proteinsVox Sanguinis, 84
E. Heegaard, I. Jensen, J. Christensen (2001)
Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9Journal of Medical Virology, 65
E. Manaresi, G. Gallinella, M. Zerbini, S. Venturoli, G. Gentilomi, M. Musiani (1999)
IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assayJournal of Medical Virology, 57
J. Blümel, I. Schmidt, W. Effenberger, H. Seitz, H. Willkommen, H. Brackmann, J. Löwer, A. Eis-Hübinger (2002)
Parvovirus B19 transmission by heat‐treated clotting factor concentratesTransfusion, 42
A. Grosse-Bley, A. Eis-Hübinger, R. Kaiser, J. Oldenburg, H. Brackmann, T. Schwarz, K. Schneweis (1994)
Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of HemophiliacsThrombosis and Haemostasis, 72
E. Heegaard, Bodil Petersen (2000)
Parvovirus B19 transmitted by bone marrowBritish Journal of Haematology, 111
M. Williams, B. Cohen, A. Beddall, K. Pasi, P. Mortimer, F. Hill (1990)
Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 58
T. Yokoyama, K. Murai, T. Murozuka, A. Wakisaka, M. Tanifuji, N. Fujii, T. Tomono (2004)
Removal of small non‐enveloped viruses by nanofiltrationVox Sanguinis, 86
R. Franssila, J. Auramo, Susanne Modrow, M. Möbs, Christian Oker-Blom, Pirjo Käpylä, M. Söderlund-Venermo, Klaus Hedman (2005)
T helper cell‐mediated interferon‐gamma expression after human parvovirus B19 infection: persisting VP2‐specific and transient VP1u‐specific activityClinical & Experimental Immunology, 142
S. Suikkanen, Mia Antila, A. Jaatinen, M. Vihinen-Ranta, M. Vuento (2003)
Release of canine parvovirus from endocytic vesicles.Virology, 316 2
O. Ennis, A. Corcoran, K. Kavanagh, B. Mahon, S. Doyle (2001)
Baculovirus expression of parvovirus B19 (B19V) NS1: utility in confirming recent infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 22 1
F. Mcomish, P. Yap, A. Jordan, H. Hart, B. Cohen, P. Simmonds (1993)
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionJournal of Clinical Microbiology, 31
A. Purmal, C. Valeri, W. Dzik, L. Pivacek, G. Ragno, Aris Lazo, J. Chapman (2002)
Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry: preclinical studiesTransfusion, 42
E. Heegaard, K. Qvortrup, J. Christensen (2002)
Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: Serologic cross‐reactivity with erythrovirus B19Journal of Medical Virology, 66
S. Doyle, A. Corcoran (2006)
The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals.The Journal of infectious diseases, 194 2
J. Gandhi (2006)
Short communication Genetic variants of parvovirus B19 identified in the United Kingdom: Implications for diagnostic testing
G. Kurtzman, B. Cohen, A. Field, R. Oseas, R. Blaese, N. Young (1989)
Immune response to B19 parvovirus and an antibody defect in persistent viral infection.The Journal of clinical investigation, 84 4
H. Sakata, H. Ihara, S. Sato, T. Kato, H. Ikeda, S. Sekiguchi (1999)
Efficiency of Donor Screening for Human Parvovirus B19 by the Receptor–Mediated Hemagglutination Assay MethodVox Sanguinis, 77
K. Brown, S. Green, J. Mayolo, N. Young, J. Bellanti, S. Smith, Tj Smith (1994)
Congenital anaemia after transplacental B19 parvovirus infectionThe Lancet, 343
P. Cassinotti, G. Siegl (2000)
Quantitative Evidence for Persistence of Human Parvovirus B19 DNA in an Immunocompetent IndividualEuropean Journal of Clinical Microbiology and Infectious Diseases, 19
S. Braham, J. Gandhi, S. Beard, B. Cohen (2004)
Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 31 1
T. Yee, Christine Lee, K. Pasi (1995)
Life-threatening human parvovirus B19 infection in immunocompetent haemophiliaThe Lancet, 345
(2007)
The Authors Journal compilation
Susan Wong, N. Young, K. Brown (2003)
Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia.The Journal of infectious diseases, 187 10
K. Groeneveld, J. Noordaa (2003)
Blood products and parvovirus B19.The Netherlands journal of medicine, 61 5
A. Moudgil, H. Shidban, C. Nast, A. Bagga, S. Aswad, S. Graham, R. Mendez, S. Jordan (1997)
Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin.Transplantation, 64 12
M. Yunoki, T. Urayama, M. Tsujikawa, Y. Sasaki, S. Abe, K. Takechi, K. Ikuta (2005)
Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparationsBritish Journal of Haematology, 128
N. Frickhofen, J. Abkowitz, M. Safford, J. Berry, J. Antunez-de-Mayolo, A. Astrow, Robert Cohen, I. Halperin, L. King, D. Mintzer, B. Cohen, N. Young (1990)
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.Annals of internal medicine, 113 12
Kirsten Weigel-Kelley, M. Yoder, A. Srivastava (2003)
α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entryBlood, 102
Armen Parsyan, Emmanuel Addo-Yobo, S. Owusu-Ofori, Henrietta Akpene, F. Sarkodie, J. Allain (2006)
Effects of transfusion on human erythrovirus B19‐susceptible or ‐infected pediatric recipients in a genotype 3–endemic areaTransfusion, 46
J. Jordan, B. Tiangco, J. Kiss, W. Koch (1998)
Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion RecipientsVox Sanguinis, 75
F. Blaeser, M. Kelly, K. Siegrist, G. Storch, R. Buller, J. Whitlock, Nga Truong, T. Chatila (2005)
Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation.Clinical immunology, 117 3
D. Erdman, B. Anderson, T. Török, T. Finkel, L. Anderson (1997)
Possible transmission of parvovirus B19 from intravenous immune globulinJournal of Medical Virology, 53
Eiji Miyagawa, T. Yoshida, Hirohiko Takahashi, K. Yamaguchi, Tohko Nagano, Yoshiko Kiriyama, Kazuo Okochi, Hiroyuki Sato (1999)
Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity.Journal of virological methods, 83 1-2
F. Bonvicini, C. Filippone, E. Manaresi, G. Gentilomi, M. Zerbini, M. Musiani, G. Gallinella (2006)
Peptide nucleic acid-based in situ hybridization assay for detection of parvovirus B19 nucleic acids.Clinical chemistry, 52 6
S. Fattet, P. Cassinotti, M. Popovic (2004)
Persistent Human Parvovirus B19 Infection in Children Under Maintenance Chemotherapy for Acute Lymphocytic LeukemiaJournal of Pediatric Hematology/Oncology, 26
K. Searle, G. Schalasta, G. Enders (1998)
Development of antibodies to the nonstructural Protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: Implications for pathogenesis doubtfulJournal of Medical Virology, 56
Ashley LaMonte, M. Paul, J. Read, M. Frederick, D. Erdman, Linda Han, L. Anderson (2004)
Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Women and Infants Transmission Study.The Journal of infectious diseases, 189 5
S. Dorsch, G. Liebisch, B. Kaufmann, P. Landenberg, J. Hoffmann, W. Drobnik, S. Modrow (2002)
The VP1 Unique Region of Parvovirus B19 and Its Constituent Phospholipase A2-Like ActivityJournal of Virology, 76
(2003)
Risk of parvovirus infection by immunoglobulin
E. Heegaard, B. Petersen, C. Heilmann, A. Hornsleth (2002)
Prevalence of Parvovirus B19 and Parvovirus V9 DNA and Antibodies in Paired Bone Marrow and Serum Samples from Healthy IndividualsJournal of Clinical Microbiology, 40
J. Kerr, V. Cunniffe (2000)
Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection.Rheumatology, 39 8
A. Servant, S. Laperche, F. Lallemand, V. Marinho, G. Maur, J. Meritet, A. Garbarg‐Chenon (2002)
Genetic Diversity within Human Erythroviruses: Identification of Three GenotypesJournal of Virology, 76
A. Zanella, F. Rossi, C. Cesana, A. Foresti, F. Nador, A. Binda, G. Lunghi, M. Cappellini, M. Furione, G. Sirchia (1995)
Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patientTransfusion, 35
F. Hayakawa, K. Imada, M. Towatari, H. Saito (2002)
Life‐threatening human parvovirus B19 infection transmitted by intravenous immune globulinBritish Journal of Haematology, 118
J. Blümel, I. Schmidt, H. Willkommen, J. Löwer (2002)
Inactivation of parvovirus B19 during pasteurization of human serum albuminTransfusion, 42
E. Manaresi, G. Gallinella, A. Labate, P. Zucchelli, D. Zaccarelli, Simone Ambretti, S. Delbarba, M. Zerbini, M. Musiani (2004)
Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donorsEpidemiology and Infection, 132
K. Brown, N. Young, B. Alving, L. Barbosa (2001)
Parvovirus B19: implications for transfusion medicine. Summary of a workshopTransfusion, 41
T. Schwarz, S. Serke, B. Hottenträger, A. Brunn, H. Baurmann, A. Kirsch, W. Stolz, D. Huhn, F. Deinhardt, M. Roggendorf (1992)
Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral bloodJournal of Virology, 66
Jaakko Parkkinen, A. Rahola, L. Bonsdorff, H. Tölö, E. Törmä (2006)
A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearanceVox Sanguinis, 90
Kazuaki Sato, E. Matsuda, K. Kamisango, Hiroaki Iwasaki, S. Matsubara, Y. Matsunaga (2000)
Development of a Hypersensitive Detection Method for Human Parvovirus B19 DNAJournal of Clinical Microbiology, 38
K. Zakrzewska, A. Azzi, G. Patou, Massimo Morfini, D. Rafanelli, J. Pattison (1992)
Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reactionBritish Journal of Haematology, 81
Y. Laurian, E. Dussaix, A. Parquet, A. Chalvon-Demersay, R. d’Oiron, G. Tchernia (1994)
Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.Nouvelle revue francaise d'hematologie, 36 6
Kirsten Weigel-Kelley, M. Yoder, A. Srivastava (2003)
Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry.Blood, 102 12
P. Cassinotti, G. Siegl, B. Michel, P. Brühlmann (1998)
Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown originJournal of Medical Virology, 56
H. Matsui, M. Sugimoto, S. Tsuji, M. Shima, J. Giddings, A. Yoshioka (1999)
Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.Journal of pediatric hematology/oncology, 21 1
A. Azzi, S. Ciappi, K. Zakvrzewska, M. Morfini, G. Mariani, P.M Mannucci (1992)
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor VIII concentratesAmerican Journal of Hematology, 39
B.J. Cohen, J. Gandhi, J.P Clewley (2006)
Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testingJournal of Clinical Virology, 36
S. Baylis, Nita Shah, P. Minor (2004)
Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.Journal of virological methods, 121 1
A. Pruß, M. Kao, U. Gohs, J. Koscielny, R. Versen, G. Pauli (2002)
Effect of gamma irradiation on human cortical bone transplants contaminated with enveloped and non-enveloped viruses.Biologicals : journal of the International Association of Biological Standardization, 30 2
Bunschoten, HL. Zaaijerb, Drimmelen, S. Vries, Roosendaal, HM. denBerg, RN. Lelieb (1998)
High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia PatientsVox Sanguinis, 74
A. Azzi, F. Maggi, K. Zakrzewska, M. Menconi, N. Pietro, V. Salotti, C. Farina, E. Andreoli, Bruno Fiorentino, Cristina Angelini, F. Corcioli, M. Bendinelli (2006)
Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purificationTransfusion, 46
Y. Yoto, T. Kudoh, K. Haseyama, N. Suzuki, Takanori Oda, T. Katoh, Tsuneo Takahashi, Sadami Sekiguchi, Shunzo Chiba (1995)
Incidence of human parvovirus B19 DNA detection in blood donorsBritish Journal of Haematology, 91
P. Ruane, Richard Edrich, Deanna Gampp, S. Keil, R. Leonard, R. Goodrich (2004)
Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and lightTransfusion, 44
A. Woolf, Bernard Cohen (1995)
Parvovirus B19 and chronic arthritis--causal or casual association?Annals of the Rheumatic Diseases, 54
J. Aubin, C. Defer, M. Vidaud, M. Montreuil, B. Flan (2000)
Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 78
N. Zhi, Ian Mills, Jun Lu, Susan Wong, C. Filippone, K. Brown (2006)
Molecular and Functional Analyses of a Human Parvovirus B19 Infectious Clone Demonstrates Essential Roles for NS1, VP1, and the 11-Kilodalton Protein in Virus Replication and InfectivityJournal of Virology, 80
A. Johnston, D. Holt, A. Hollander, F. Woude, A. Cohen, GaryC. Yee, D. Lowenthal (1995)
Effect of grapefruit juice on blood cyclosporin concentrationThe Lancet, 346
M. Yunoki, M. Tsujikawa, T. Urayama, Y. Sasaki, M. Morita, H. Tanaka, S. Hattori, K. Takechi, K. Ikuta (2003)
Heat sensitivity of human parvovirus B19Vox Sanguinis, 84
N. Boschetti, I. Niederhauser, C. Kempf, A. Stühler, J. Löwer, J. Blümel (2004)
Different susceptibility of B19 virus and mice minute virus to low pH treatmentTransfusion, 44
M. Hino, O. Ishiko, K. Honda, T. Yamane, K. Ohta, T. Takubo, N. Tatsumi (2000)
Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgeryBritish Journal of Haematology, 108
C. Wakamatsu, F. Takakura, E. Kojima, Y. Kiriyama, N. Goto, K. Matsumoto, M. Oyama, Hiroyuki Sato, Kazuo Okochi, Yoshiaki Maeda (1999)
Screening of Blood Donors for Human Parvovirus B19 and Characterization of the ResultsVox Sanguinis, 76
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini, R. Musso, R. Santoro, M. Schiavoni (1997)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilizationTransfusion, 37
summary Erythrovirus (parvovirus) B19 (B19) is a common human pathogen. It is a non‐enveloped single‐strand DNA virus packaging its genome in small tight capsids consisting of viral VP1 and VP2 proteins. It is now accepted that B19 is a relatively quickly evolving virus having diverged in several genetic variants recently identified. The main route of B19 transmission is respiratory, with a majority of infections occurring during childhood and manifesting as erythema infectiousum. B19 can also be transmitted vertically and via blood transfusion and organ transplantation. The majority of adult populations show immunological evidence of previous exposure to B19. Although the immune response is able to clear infection and provide life‐long protection against B19, recent data suggest that in some, if not the majority, of individuals the acute phase of infection is followed by viral persistence in the blood or other tissues regardless of the host’s immunocompetence. Transmission of B19 by blood and blood products and its resistance to common viral inactivation methods raises several blood safety questions, still unanswered. The diversity of B19 strains and the ability of the virus to persist in the presence of specific antibodies raise the issue of transmissibility by transfusion not so much to immunocompetent recipients but rather to the large proportion of recipients in whom there is some degree of immunodeficiency. The ability of the virus to reactivate in immunodeficient recipients may create difficulties in differentiating between transfusion transmission and reactivation.
Transfusion Medicine – Wiley
Published: Jan 1, 2007
Keywords: ; ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.